Transthyretin amyloidosis is a fatal disorder that is characterized primarily by progressive neuropathy and cardiomyopathy. It occurs in both a mutant form (with autosomal dominant inheritance) and a wild-type form (with predominant cardiac involvement). This article guides clinicians as to when the disease should be suspected, describes the appropriate diagnostic evaluation for those with known or suspected amyloidosis, and reviews the interventions currently available for affected patients.
Keywords: familial amyloid cardiomyopathy; familial amyloid polyneuropathy; genetics; liver transplantation.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.